China-Based Biotech Selects Medidata Platform
Henlius Biotechnology has selected Medidata’s Medidata Clinical Cloud® platform for its Phase III oncology clinical trial in China.
China-based Shanghai Henlius Biotechnology Co. Ltd. (Henlius) has selected Medidata’s Medidata Clinical Cloud® platform, specifically Medidata Rave® (electronic data capture) and Medidata Balance® (randomization and trial supply management) in its Phase III oncology clinical trial in China.
Henlius focuses on the development, production and commercialization of monoclonal antibody drugs for a number of therapeutic areas, including oncology and auto-immune diseases.
Read the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025